Reg­u­la­tors throw up an­oth­er hur­dle to Roche’s $4.3B Spark ac­qui­si­tion as ques­tions per­co­late over he­mo­phil­ia mar­ket dom­i­na­tion

Don’t look for Roche’s $4.3 bil­lion Spark $ONCE buy­out — an­nounced 7 months ago — to close any­time in the very near fu­ture.

The UK Com­pe­ti­tion and Mar­kets Au­thor­i­ty just opened a 2-week pub­lic com­ment pe­ri­od on the tie-up, look­ing for some opin­ions on the phar­ma gi­ant’s com­pet­i­tive po­si­tion if the deal goes through. 

In an an­nounce­ment to­day the CMA re­marked that they were so­lic­it­ing re­marks on “whether the cre­ation of that sit­u­a­tion may be ex­pect­ed to re­sult, in a sub­stan­tial less­en­ing of com­pe­ti­tion with­in any mar­ket or mar­kets in the Unit­ed King­dom for goods or ser­vices.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.